Last Of The Primary Care Blockbusters? New Antithrombotics Line Up To Unseat Warfarin, Heparins, Plavix
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Although the mainstays of antithrombotic therapy have remained the same for decades, a lengthy R&D assault by pharma – including some of the largest clinical trials ever conducted – has produced potential game-changers that have made it to FDA review for both major blood clot approaches: anticoagulation and platelet inhibition.
You may also be interested in...
Oral Factor Xa Inhibitors Come Closer To Offering An Alternative To Warfarin
The field for novel oral anticoagulants - already a popular target as Big Pharma grasps for primary care products - has become even more attractive with a recent decision by CMS not to cover diagnostics to aid with warfarin use
J&J Pharma Presents a Robust Pipeline and Outlines A New R&D Structure
In a wide-ranging presentation to Wall Street, the company highlights key new products in development and an R&D strategy built around five therapeutic areas.
J&J Pharma Presents Robust Pipeline And Outlines New R&D Structure
In a wide-ranging presentation to Wall Street, the company highlights key new products in development and an R&D strategy built around five therapeutic areas